HealthDay News — For patients with type 2 diabetes and acute coronary syndrome (ACS), adiponectin concentration is associated with increased risk of certain cardiovascular (CV) outcomes, according to a study published online in Diabetes, Obesity and Metabolism.
Brian A. Bergmark, MD, from the Brigham and Women’s Hospital and Harvard Medical School in Boston, and colleagues examined adiponectin and CV outcomes in 5,213 patients with type 2 diabetes enrolled 15 to 90 days after ACS. The authors assessed event rates at 18 months.
The researchers found that, compared to patients with baseline adiponectin in the lowest quartile, patients with the highest baseline adiponectin concentration (Q4) had significantly increased risks of CV death (8.4% vs 1.7%), hospitalization for heart failure (7.5% vs 1.7%), and all-cause mortality (10.8% vs 2.4%) (all P <.0001). The significant associations persisted after adjustment for age, sex, index event, heart failure, estimated glomerular filtration rate, and hypertension, with hazard ratios of 2.43, 2.45, and 2.44 for CV death, all-cause mortality, and heart failure, respectively, for adiponectin concentration in Q4, without change after stratification by body mass index. The rate of myocardial infarction or stroke did not differ significantly.
“Adiponectin concentration was independently associated with increased risk of CV death, all-cause mortality, and heart failure hospitalization,” the authors write. “The relationship between adiponectin and CV outcomes is complex and deserves further study.”
Several authors disclosed financial ties to the pharmaceutical industry.
Bergmark B, Cannon CP, White WB, et al. Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial [published online February 14, 2017]. Diabetes Obes Metab. doi: 10.1111/dom.12905